BioCryst Pharmaceuticals | BCRX - 市值



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.75B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


市值 更改 日
Alnylam Pharmaceuticals USD 40.19B 3.96B 2026-06
BioCryst Pharmaceuticals USD 2.54B 880M 2026-06
Chugai Pharma JPY 12.65T 1.81T 2026-06
DBV Technologies USD 1.23B 327M 2026-03
Enanta Pharmaceuticals USD 122M 98M 2024-12
Gilead Sciences USD 156.86B 16.13B 2026-06
GlaxoSmithKline GBP 80.14B 3.66B 2026-06
Glaxosmithkline GBP 109.29B 9.36B 2026-03
Incyte USD 22.65B 3.92B 2026-06
Ionis Pharmaceuticals USD 13.1B 642M 2026-06
Karyopharm Therapeutics USD 126M 9M 2026-03
Neurocrine Biosciences USD 16.95B 3.7B 2026-06
Novavax USD 1.09B 316M 2025-12
Regeneron Pharmaceuticals USD 65.37B 16.31B 2026-06
Roche Holding CHF 270B 3.66B 2026-06
Sarepta Therapeutics USD 1.9B 388M 2026-06
Ultragenyx Pharmaceutical USD 3.29B 1.23B 2026-06
Vertex Pharmaceuticals USD 126.07B 12.49B 2026-06